Boai NKY Medical Holdings Ltd. (300109.SZ)
CNY 17.2
(6.57%)
CNY 17.2
(6.57%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 499.66 Million CNY | -16.2% |
| 2022 | 596.28 Million CNY | 1.11% |
| 2021 | 589.76 Million CNY | -44.84% |
| 2020 | 1.06 Billion CNY | -6.54% |
| 2019 | 1.14 Billion CNY | 11.42% |
| 2018 | 1.02 Billion CNY | 56.48% |
| 2017 | 656.22 Million CNY | 687.58% |
| 2016 | 83.32 Million CNY | 13.97% |
| 2015 | 73.1 Million CNY | -1.71% |
| 2014 | 74.38 Million CNY | 63.18% |
| 2013 | 45.58 Million CNY | -0.51% |
| 2012 | 45.81 Million CNY | 18.06% |
| 2011 | 38.8 Million CNY | 57.75% |
| 2010 | 24.59 Million CNY | -49.45% |
| 2009 | 48.66 Million CNY | 2.4% |
| 2008 | 47.52 Million CNY | -2.7% |
| 2007 | 48.84 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 818.1 Million CNY | -16.73% |
| 2024 Q1 | 461.58 Million CNY | -7.62% |
| 2024 Q2 | 982.52 Million CNY | 112.86% |
| 2023 Q2 | 498.69 Million CNY | -10.48% |
| 2023 Q4 | 499.66 Million CNY | -6.75% |
| 2023 Q1 | 557.06 Million CNY | -6.58% |
| 2023 FY | 499.66 Million CNY | -16.2% |
| 2023 Q3 | 535.84 Million CNY | 7.45% |
| 2022 Q4 | 596.28 Million CNY | 21.15% |
| 2022 Q3 | 492.2 Million CNY | -7.3% |
| 2022 Q1 | 494.08 Million CNY | -16.22% |
| 2022 Q2 | 530.98 Million CNY | 7.47% |
| 2022 FY | 596.28 Million CNY | 1.11% |
| 2021 Q2 | 1.19 Billion CNY | 8.47% |
| 2021 FY | 589.76 Million CNY | -44.84% |
| 2021 Q1 | 1.1 Billion CNY | 3.03% |
| 2021 Q3 | 1.17 Billion CNY | -1.51% |
| 2021 Q4 | 589.76 Million CNY | -49.89% |
| 2020 FY | 1.06 Billion CNY | -6.54% |
| 2020 Q3 | 1.02 Billion CNY | -8.59% |
| 2020 Q2 | 1.12 Billion CNY | -1.77% |
| 2020 Q1 | 1.14 Billion CNY | -0.18% |
| 2020 Q4 | 1.06 Billion CNY | 4.28% |
| 2019 Q2 | 1.05 Billion CNY | 1.24% |
| 2019 Q4 | 1.14 Billion CNY | 7.97% |
| 2019 FY | 1.14 Billion CNY | 11.42% |
| 2019 Q1 | 1.04 Billion CNY | 1.28% |
| 2019 Q3 | 1.05 Billion CNY | 0.63% |
| 2018 Q4 | 1.02 Billion CNY | 14.59% |
| 2018 FY | 1.02 Billion CNY | 56.48% |
| 2018 Q3 | 896.13 Million CNY | 7.93% |
| 2018 Q1 | 679.61 Million CNY | 3.56% |
| 2018 Q2 | 830.29 Million CNY | 22.17% |
| 2017 Q3 | 278.23 Million CNY | 155.32% |
| 2017 Q1 | 96.95 Million CNY | 16.36% |
| 2017 Q2 | 108.97 Million CNY | 12.4% |
| 2017 FY | 656.22 Million CNY | 687.58% |
| 2017 Q4 | 656.22 Million CNY | 135.85% |
| 2016 Q3 | 87.53 Million CNY | -76.49% |
| 2016 Q2 | 372.31 Million CNY | -1.21% |
| 2016 Q4 | 83.32 Million CNY | -4.81% |
| 2016 FY | 83.32 Million CNY | 13.97% |
| 2016 Q1 | 376.87 Million CNY | 415.5% |
| 2015 Q1 | 71.68 Million CNY | -3.63% |
| 2015 FY | 73.1 Million CNY | -1.71% |
| 2015 Q2 | 64.32 Million CNY | -10.27% |
| 2015 Q3 | 83.54 Million CNY | 29.88% |
| 2015 Q4 | 73.1 Million CNY | -12.49% |
| 2014 Q2 | 48.45 Million CNY | 10.17% |
| 2014 FY | 74.38 Million CNY | 63.18% |
| 2014 Q4 | 74.38 Million CNY | 35.48% |
| 2014 Q3 | 54.9 Million CNY | 13.3% |
| 2014 Q1 | 43.98 Million CNY | -3.51% |
| 2013 Q3 | 27.86 Million CNY | 4.83% |
| 2013 Q1 | 36.03 Million CNY | -21.34% |
| 2013 FY | 45.58 Million CNY | -0.51% |
| 2013 Q4 | 45.58 Million CNY | 63.58% |
| 2013 Q2 | 26.58 Million CNY | -26.23% |
| 2012 Q2 | 30.49 Million CNY | -24.64% |
| 2012 FY | 45.81 Million CNY | 18.06% |
| 2012 Q1 | 40.46 Million CNY | 4.29% |
| 2012 Q4 | 45.81 Million CNY | 16.62% |
| 2012 Q3 | 39.28 Million CNY | 28.81% |
| 2011 Q2 | 30.2 Million CNY | 22.18% |
| 2011 Q3 | 49.84 Million CNY | 65.02% |
| 2011 FY | 38.8 Million CNY | 57.75% |
| 2011 Q4 | 38.8 Million CNY | -22.15% |
| 2011 Q1 | 24.72 Million CNY | 0.5% |
| 2010 Q3 | 27.08 Million CNY | -36.68% |
| 2010 Q2 | 42.77 Million CNY | -11.37% |
| 2010 FY | 24.59 Million CNY | -49.45% |
| 2010 Q4 | 24.59 Million CNY | -9.17% |
| 2010 Q1 | 48.25 Million CNY | -0.82% |
| 2009 Q4 | 48.66 Million CNY | 0.0% |
| 2009 FY | 48.66 Million CNY | 2.4% |
| 2008 FY | 47.52 Million CNY | -2.7% |
| 2007 FY | 48.84 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 9.12 Billion CNY | 94.526% |
| Zhejiang Zhenyuan Share Co., Ltd. | 974.86 Million CNY | 48.746% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 1.21 Billion CNY | 58.843% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 1.63 Billion CNY | 69.478% |
| Yifan Pharmaceutical Co., Ltd. | 3.14 Billion CNY | 84.112% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 84.57 Million CNY | -490.766% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 13.22 Billion CNY | 96.221% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 762.32 Million CNY | 34.455% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 258.46 Million CNY | -93.322% |